RT Journal Article SR Electronic T1 First cases of infection with the 21L/BA.2 Omicron variant in Marseille, France JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.02.08.22270495 DO 10.1101/2022.02.08.22270495 A1 Colson, Philippe A1 Delerce, Jérémy A1 Beye, Mamadou A1 Levasseur, Anthony A1 Boschi, Céline A1 Houhamdi, Linda A1 Tissot-Dupont, Hervé A1 Yahi, Nouara A1 Million, Matthieu A1 La Scola, Bernard A1 Fantini, Jacques A1 Raoult, Didier A1 Fournier, Pierre-Edouard YR 2022 UL http://medrxiv.org/content/early/2022/02/10/2022.02.08.22270495.abstract AB The SARS-CoV-2 21K/BA.1, 21L/BA.2, and BA.3 Omicron variants have recently emerged worldwide. To date, the 21L/BA.2 Omicron variant has remained very minority globally but became predominant in Denmark instead of the 21K/BA.1 variant. Here we describe the first cases diagnosed with this variant in south-eastern France. We identified thirteen cases using variant-specific qPCR and next-generation sequencing between 28/11/2021 and 31/01/2022, the first two cases being diagnosed in travellers returning from Tanzania. Overall, viral genomes displayed a mean (±standard deviation) number of 65.9±2.5 (range, 61-69) nucleotide substitutions and 31.0±8.3 (27-50) nucleotide deletions, resulting in 49.6±2.2 (45-52) amino acid substitutions (including 28 in the spike protein) and 12.4±1.1 (12-15) amino acid deletions. Phylogeny showed the distribution in three different clusters of these genomes, which were most closely related to genomes from England and South Africa, from Singapore and Nepal, or from France and Denmark. Structural predictions pointed out a significant enlargement and flattening of the 21L/BA.2 N-terminal domain surface compared with that of the 21K/BA.2 Omicron variant, which may facilitate initial viral interactions with lipid rafts. Close surveillance is needed at global, country and center scales to monitor the incidence and clinical outcome of the 21L/BA.2 Omicron variant.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the French Government under the Investments for the Future program managed by the National Agency for Research (ANR), Mediterranee-Infection 10-IAHU-03, and was also supported by Region Provence Alpes Cote d'Azur and European funding FEDER PRIMMI (Fonds Europeen de Developpement Regional-Plateformes de Recherche et d'Innovation Mutualisees Mediterranee Infection), FEDER PA 0000320 PRIMMI, by the Emergen French consortium (https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/consortium-emergen.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethics committee of University Hospital Institute Mediterranee Infection (No. 2022-008). Access to biological and registry data of patients issued from the hospital information system was approved by the data protection committee of Assistance Publique-Hopitaux de Marseille and recorded in the European General Data Protection Regulation registry under number RGPD/APHM 2019-73.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenome sequences described here were deposited in the GISAID sequence database (https://www.gisaid.org/).